title: [Results of 2 multicenter therapy studies in inoperable non-small cell bronchial cancer].
abstract: A total of 166 patients with non-small cell lung cancer (NSCLC) were included in two multicenter trials testing different treatment regimens. In study I, 116 patients received 4 cycles of aggressive polychemotherapy consisting of cis-platinum 100 mg/m2 (day 1), etoposide 100 mg/m2 (days 4-6), and vindesine 3 mg/m2 (day 1) (CEV); patients without distant metastases subsequently received chest irradiation with 50 Gy. In study II, 50 patients were treated with monochemotherapy consisting of etoposide 250 mg/m2 (days 1-3), and ifosfamide 5 g/m2 as 24-h infusion (day 29). While this program was repeated in responders with extensive disease (ED), patients with limited disease (LD) subsequently received chest irradiation with 50 Gy using 20 mg/m2 cis-platinum weekly as a radiosensitizer. Response rates (CR + PR) to chemotherapy were higher in study I than in study II, and were 26% (CR 3%) vs. 8% (CR 0%) for all patients, 18% (CR 0%) vs. 4% (CR 0%) for ED, and 45% (CR 11%) vs. 13% (CR 0%) for LD. The increase in response rates by radiotherapy was marginal in study I (CR + PR 47%, CR 18%), but remarkable in study II (CR + PR 42%, CR 29%). While median survival was slightly longer in study I than in study II for ED (7.7 vs. 6.6 months) and LD (14.4 vs. 12.0 months), the 2-year survival rate was in favor of study II (10% vs. 25%). Toxicity was clearly more pronounced in study I, including 3 lethal complications and 16 discontinuations of therapy due to side effects or refusal. Thus, while in ED the efficacy of both treatment regimens was very restricted, in LD radiotherapy with cis-platinum as a radiosensitizer achieved a relatively high 2-year survival rate which justifies further testing of this treatment strategy.
authors.affiliation: Abteilung Hämatologie/Onkologie, Philipps-Universität, Marburg.
authors.forename: M
authors.initials: M
authors.lastname: Wolf
authors.forename: K
authors.initials: K
authors.lastname: Havemann
authors.forename: D
authors.initials: D
authors.lastname: Stalleicken
authors.forename: C
authors.initials: C
authors.lastname: Gropp
authors.forename: M
authors.initials: M
authors.lastname: Maasberg
authors.forename: K
authors.initials: K
authors.lastname: Hans
authors.forename: F
authors.initials: F
authors.lastname: von Bültzingslöwen
authors.forename: H
authors.initials: H
authors.lastname: Klasen
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: M
authors.initials: M
authors.lastname: Schroeder
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D005047:Etoposide; D002945:Cisplatin; D014751:Vindesine; D007069:Ifosfamide
vernacular_title: Ergebnisse zweier multizentrischer Therapiestudien beim inoperablen nichtkleinzelligen Bronchialkarzinom.